PLAT and stroke disorder: At present, recombinant tissue plasminogen activator (r-TPA) is used for thrombolytic therapy; however, with the limitation of usage within 4.5 h after the onset of stroke, only 3–5% of stroke patients meet the criteria and use r-TPA in a timely fashion (Wardlaw et al., 2014; Marlier et al., 2015; Moretti et al., 2015; Campbell et al., 2019; Campbell and Khatri, 2020).